Epidemiological Assessment and Challenges of the COVID-19 Pandemic in Nigeria

Main Article Content

Stephen Olaide Aremu
Emmanuel Olumuyiwa Onifade
Babatunde Fatoke
Samuel Olusegun Itodo
Oluwatosin Oladipo
Olufisayo Bademosi
Temilade Taiwo Oleni
Tosin Adebola Ode
Ebenezer Oluwasanmi Abeleje
Adebowale Olasehinde Folorunso


The COVID-19 which belongs to the coronaviridae family has continued to spread in a geometric progression version. The disease that originated from Wuhan, Hubei, China has spread to all the continents of the World except Antarctica continent. As of the 5th of August, 2020 there are over 18 million reported cases of COVID-19 from 214 countries and territories of the world. More than 10 million people have recovered while approximately 696,147 people have died due to COVID-19. This review provides general information on the COVID-19 and gives deep insight into the course of the disease, interventions challenges and possible solutions in Nigeria “the giant of Africa”.

Scientific databases including Science Direct, Pub Med, Elsevier, Scopus, and Nature were explored. Data has also been accessed from case reports, newspaper reports, internet data, World Health Organisation (WHO) reports, Centre of Disease Control (CDCs) and Nigerian Centre of Disease Control (NCDCs) reports. US National Library of Medicine, Clinicaltrials.gov, has been accessed to get information about ongoing clinical trials. The literature survey started in the first week of April, 2020 and was completed in the first week of August, 2020. The clinical symptoms of COVID-19 patients are generally categorized as critical, severe, moderate and mild or even asymptomatic in descending order in terms of severity. Predictions from experts in different parts of the World concerning the possible impact of the disease in Africa have been on the downside which is due to a lot of glaring factors including poor health facilities and services. 

COVID-19, coronaviridae, pandemic, disease, epidemiology, Nigeria.

Article Details

How to Cite
Aremu, S. O., Onifade, E. O., Fatoke, B., Itodo, S. O., Oladipo, O., Bademosi, O., Oleni, T. T., Ode, T. A., Abeleje, E. O., & Folorunso, A. O. (2020). Epidemiological Assessment and Challenges of the COVID-19 Pandemic in Nigeria. Microbiology Research Journal International, 30(9), 11-29. https://doi.org/10.9734/mrji/2020/v30i930259
Review Article


Singh A, Shaikh A, Singh R, Singh AK. COVID-19: From bench to bed side. Diabetes Metab. Syndr. Clin. Res. Rev. 2020;14(4):277–281. DOI: 10.1016/j.dsx.2020.04.011

Xie M, Chen Q. Insight into 2019 novel coronavirus — An updated interim review and lessons from SARS-CoV and MERS-CoV. Int. J. Infect. Dis. 2020;94:119–124. DOI: 10.1016/j.ijid.2020.03.071

Kapata N et al., Is Africa prepared for tackling the COVID-19 (SARS-CoV-2) epidemic. Lessons from past outbreaks, ongoing pan-African public health efforts, and implications for the future. Int. J. Infect. Dis. 2020;93:233–236. DOI: 10.1016/j.ijid.2020.02.049

Nguyen T, Duong Bang D, Wolff A. 2019 novel coronavirus disease (COVID-19): Paving the road for rapid detection and point-of-care diagnostics. Micromachine. 2020;11(3),3. DOI: 10.3390/mi11030306

COVID-19 situation reports. (accessed Apr. 29, 2020). Available:https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports

Coronavirus disease (COVID-19) situation reports. (accessed Aug. 07, 2020). Available:https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports

Ebenso B, Out A. Can Nigeria contain the COVID-19 outbreak using lessons from recent epidemics?. Lancet Glob. Health; 2020. DOI: 10.1016/S2214-109X(20)30101-7

Africa CDC - COVID-19 daily updates. Africa CDC. (accessed Apr. 27, 2020). Available:https://africacdc.org/covid-19/

(PDF) more preparedness on coronavirus disease-2019 (COVID-19) in Nigeria. ResearchGate. (accessed Apr. 27, 2020). Available:https://www.researchgate.net/publication/340260938_More_Preparedness_on_Coronavirus_Disease-2019_COVID-19_in_Nigeria

Adegboye O, Adekunle AI, Gayawan E. Novel coronavirus in Nigeria: Epidemiological analysis of the first 45 days of the pandemic. medRxiv; 2020; 14:20064949. DOI: 10.1101/2020.04.14.20064949

Italian doctors call for protecting healthcare workers and boosting community surveillance during covid-19 outbreak | The BMJ. (accessed Sep. 21, 2020). Available:https://www.bmj.com/content/368/bmj.m1254

Why Africa’s coronavirus outbreak appears slower than anticipated World — The Guardian Nigeria News – Nigeria and World News. (accessed Apr. 28, 2020). Available:https://guardian.ng/news/why-africas-coronavirus-outbreak-appears-slower-than-anticipated/

NCDC coronavirus COVID-19 microsite. (accessed May 02, 2020). Available: https://covid19.ncdc.gov.ng/

Tu H, Tu S, Gao S, Shao A, Sheng J. The epidemiological and clinical features of COVID-19 and lessons from this global infectious public health event. J. Infect; 2020. DOI: 10.1016/j.jinf.2020.04.011

Tyrrell DA, Bynoe ML. Cultivation of viruses from a high proportion of patients with colds. Lancet Lond. Engl. 1966;1, 7428:76–77. DOI: 10.1016/s0140-6736(66)92364-6

Velavan TP, Meyer CG. The COVID-19 epidemic. Trop. Med. Int. Health TM IH. 2020;25(3):278–280. DOI: 10.1111/tmi.13383

Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol. 2019;17(3):181–192. DOI: 10.1038/s41579-018-0118-9

Zumla A, Chan JFW, Azhar EI, Hui DSC, Yuen K-Y. Coronaviruses — drug discovery and therapeutic options. Nat. Rev. Drug Discov. 2016;15:5,5. DOI: 10.1038/nrd.2015.37

Rabi FA, Zoubi MSAl, Kasasbeh GA, Salameh DM, Al-Nasser AD. SARS-CoV-2 and coronavirus disease 2019: What We know so far. Pathogens. 2020;9(3):3. DOI: 10.3390/pathogens9030231

Woo PCY et al. Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus. J. Virol. 2012;86(7):3995–4008. DOI: 10.1128/JVI.06540-11

Tang Q, Song Y, Shi M, Cheng Y, Zhang W, Xia X-Q. Inferring the hosts of coronavirus using dual statistical models based on nucleotide composition. Sci. Rep. 2015;5(1):1. DOI: 10.1038/srep17155

Gorbalenya AE et al. Severe acute respiratory syndrome-related coronavirus: The species and its viruses – A statement of the coronavirus study group. BioRxiv. 2020;937862. DOI: 10.1101/2020.02.07.937862

Lai C-C, Shih T-P, Ko W-C, Tang H-J, Hsueh P-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int. J. Antimicrob. Agents. 2020;55(3):105924. DOI: 10.1016/j.ijantimicag.2020.105924

Wang L, Wang Y, Ye D, Liu Q. Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence. Int. J. Antimicrob. Agents. 2020;105948. DOI: 10.1016/j.ijantimicag.2020.105948

Su S et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016;24(6):490–502. DOI: 10.1016/j.tim.2016.03.003

Yoshimoto FK. The proteins of severe acute respiratory syndrome coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19. Protein J. 2020;39(3):198–216. DOI: 10.1007/s10930-020-09901-4

Forni D, Cagliani R, Clerici M, Sironi M. Molecular evolution of human coronavirus genomes. Trends Microbiol. 2017;25(1): 35–48. DOI: 10.1016/j.tim.2016.09.001

Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin–angiotensin–aldosterone system blockers and the risk of Covid-19. N. Engl. J. Med. 2020;382(25):2431–2440. DOI: 10.1056/NEJMoa2006923

Tomasoni D et al. COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease. Eur. J. Heart Fail. 2020;22(6):957–966. DOI: 10.1002/ejhf.1871

Sheshe S et al. Mechanism of antiviral immune response and COVID-19 infection. Asian J. Immunol. 2020;1–8.

Zhou P et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579: 7798,7798. DOI: 10.1038/s41586-020-2012-7

Zu ZY et al. Coronavirus disease 2019 (COVID-19): A perspective from China. Radiology. 2020;200490. DOI: 10.1148/radiol.2020200490

Baz SE, Imziln B. Can aerosols and wastewater be considered as potential transmissional sources of COVID-19 to humans?. Eur. J. Environ. Public Health. 2020;4(2):em0047. DOI: 10.29333/ejeph/8324

Guan W-J et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020;382(18):1708–1720, 30. DOI: 10.1056/NEJMoa2002032

Kang S et al. Recent progress in understanding 2019 novel coronavirus (SARS-CoV-2) associated with human respiratory disease: Detection, mechanisms and treatment. Int. J. Antimicrob. Agents. 2020;105950. DOI: 10.1016/j.ijantimicag.2020.105950

Kratzel A et al. Inactivation of severe acute respiratory syndrome coronavirus 2 by WHO-recommended hand rub formulations and alcohols. Emerging Infectious Diseases journal – CDC. 2020;26:7. DOI: 10.3201/eid2607.200915

Petrosillo N, Viceconte G, Ergonul O, Ippolito G, Petersen E. COVID-19, SARS and MERS: Are they closely related?. Clin. Microbiol. Infect. 2020;26(6):729–734. DOI: 10.1016/j.cmi.2020.03.026

Lai C-C, Wang C-Y, Wang Y-H, Hsueh S-C, Ko W-C, Hsueh P-R. Global epidemiology of coronavirus disease 2019 (COVID-19): Disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status. Int. J. Antimicrob. Agents. 2020;55(4): 105946. DOI: 10.1016/j.ijantimicag.2020.105946

M. da S. Cespedes, J. C. R. P. de Souza, da SM. Cespedes, R JC. de Souza P. Sars-CoV-2: A clinical update – II. Rev. Assoc. Médica Bras. 2020;66(4): 547–557. DOI: 10.1590/1806-9282.66.4.547

Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in Covid-19. N. Engl. J. Med. 2020;382(25):e102. DOI: 10.1056/NEJMoa2007621

Harapan H et al. Coronavirus disease 2019 (COVID-19): A literature review. J. Infect. Public Health; 2020. DOI: 10.1016/j.jiph.2020.03.019.

Kowalik MM, Trzonkowski P, Łasińska-Kowara M, Mital A, Smiatacz T, Jaguszewski M. COVID-19 — Toward a comprehensive understanding of the disease. Cardiol. J. 2020;27(2):2. DOI: 10.5603/CJ.a2020.0065

Gupta AK et al. Current perspectives on coronavirus disease 2019 and cardiovascular disease: A white paper by the jaha editors. J. Am. Heart Assoc. Cardiovasc. Cerebrovasc. Dis. 2020;9:12. DOI: 10.1161/JAHA.120.017013

Cardiovascular disease and COVID-19: Les liaisons dangereuses - Andrea Barison, Alberto Aimo, Vincenzo Castiglione, Chiara Arzilli, Josep Lupón, Pau Codina, Evelyn Santiago-Vacas, Germán Cediel, Michele Emdin, Antoni Bayes-Genis; 2020. Available:https://journals.sagepub.com/doi/full/10.1177/2047487320924501 (accessed Sep. 22, 2020).

Guzik TJ et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc. Res. 2020;116(10): 1666–1687. DOI: 10.1093/cvr/cvaa106

Xiong T-Y, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur. Heart J. 2020;41(19):1798–1800. DOI: 10.1093/eurheartj/ehaa231

Bauch CT, Lloyd-Smith JO, Coffee MP, Galvani A P. Dynamically modeling SARS and other newly emerging respiratory illnesses: Past, present, and future. Epidemiol. Camb. Mass. 2005;16(6):791–801. DOI:10.1097/01.ede.0000181633.80269.4c

Payus AO, Lin CLS, Noh MM, Jeffree MS, Ali RA. SARS-CoV-2 infection of the nervous system: A review of the literature on neurological involvement in novel coronavirus disease-(COVID-19). Bosn. J. Basic Med. Sci. 2020;20(3):283–292. DOI: 10.17305/bjbms.2020.4860

Zhou P et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. BioRxiv. 2020;914952. DOI: 10.1101/2020.01.22.914952

Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J. Autoimmun. 2020;109:102433. DOI: 10.1016/j.jaut.2020.102433

Combination of RT‐qPCR testing and clinical features for diagnosis of COVID‐19 facilitates management of SARS‐CoV‐2 outbreak - Wang - Journal of Medical Virology - Wiley Online Library; 2020. (accessed May 02, 2020). Available:https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.25721

Bruning AHL et al. Rapid detection and monitoring of human coronavirus infections. New Microbes New Infect. 2018;24:52–55. DOI: 10.1016/j.nmni.2018.04.007

Lomoro P et al. COVID-19 pneumonia manifestations at the admission on chest ultrasound, radiographs, and CT: single-center study and comprehensive radiologic literature review. Eur. J. Radiol. Open. 2020;7:100231. DOI: 10.1016/j.ejro.2020.100231

Makoni M. COVID-19 vaccine trials in Africa. Lancet Respir. Med; 2020. DOI: 10.1016/S2213-2600(20)30401-X

Li X et al. Extracorporeal membrane oxygenation for coronavirus disease 2019 in Shanghai, China. Asaio J. 2020;66(5): 475–481. DOI: 10.1097/MAT.0000000000001172

Cho CH et al. Evaluation of the AdvanSureTM real-time RT-PCR compared with culture and Seeplex RV15 for simultaneous detection of respiratory viruses. Diagn. Microbiol. Infect. Dis. 2014;79(1):14–18. DOI: 10.1016/j.diagmicrobio.2014.01.016

Gaunt ER, Hardie A, Claas ECJ, Simmonds P, Templeton KE. Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method. J. Clin. Microbiol. 2010;48(8):2940– 2947. DOI: 10.1128/JCM.00636-10.

Sheikhi K, Shirzadfar H, Sheikhi M. A review on novel coronavirus (Covid-19): symptoms, transmission and diagnosis tests. Res. Infect. Dis. Trop. Med. 2020;2(1):1.

Hu Z et al. Clinical use of short-course and low-dose corticosteroids in patients with non-severe COVID-19 during pneumonia progression. Front. Public Health. 2020;8. DOI: 10.3389/fpubh.2020.00355

Rogers JP et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: A systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020;7(7):611–627. DOI: 10.1016/S2215-0366(20)30203-0

Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A systematic review. J. Med. Virol. 2020;92(5):479–490. DOI: 10.1002/jmv.25707

Alhazzani W et al. Surviving sepsis campaign: Guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med. 2020;1–34. DOI: 10.1007/s00134-020-06022-5

Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics. 1972;50(4):515–525.

Scavone C et al. Current pharmacological treatments for COVID‐19: What’s next? Br. J. Pharmacol; 2020. DOI: 10.1111/bph.15072

Czock D, Keller F, Rasche FM, Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin. Pharmacokinet. 2005;44(1):61–98. DOI: 10.2165/00003088-200544010-00003

Rismanbaf A. Potential treatments for COVID-19; A narrative literature review. Arch. Acad. Emerg. Med. 2020;8:1. Accessed: Sep. 22, 2020. [Online]. Available:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7085862/

Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A. New insights into the antiviral effects of chloroquine. Lancet Infect. Dis. 2006;6(2):67–69. DOI: 10.1016/S1473-3099(06)70361-9

Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci. Trends. 2020;14(1):72–73. DOI: 10.5582/bst.2020.01047

Colson P, Rolain J-M, Raoult D. Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int. J. Antimicrob. Agents. 2020;55(3):105923. DOI: 10.1016/j.ijantimicag.2020.105923

Devaux CA, Rolain J-M, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: What to expect for COVID-19? Int. J. Antimicrob. Agents. 2020;55(5):105938.

Yousefifard M et al. Antiviral therapy in management of COVID-19: A systematic review on current evidence. Arch. Acad. Emerg. Med. 2020;8:1. Accessed: Sep. 22, 2020. [Online]. Available:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7156260/

Touret F, de Lamballerie X. Of chloroquine and COVID-19. Antiviral Res. 2020;177: 104762. DOI: 10.1016/j.antiviral.2020.104762

Sharma A, Tiwari S, Deb MK, Marty JL. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): A global pandemic and treatment strategies. Int. J. Antimicrob. Agents. 2020;56(2):106054. DOI: 10.1016/j.ijantimicag.2020.106054

Vincent MJ et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol. J. 2005;2. DOI: 10.1186/1743-422X-2-69

Inglot AD. Comparison of the antiviral activity in vitro of some non-steroidal anti-inflammatory drugs. J. Gen. Virol. 1969;4(2):203–214. DOI: 10.1099/0022-1317-4-2-203

Miller DK, Lenard J. Antihistaminics, local anesthetics, and other amines as antiviral agents. Proc. Natl. Acad. Sci. U. S. A. 1981;78(6):3605–3609.

Shimizu Y, Yamamoto S, Homma M, Ishida N. Effect of chloroquine on the growth of animal viruses. Arch. Für Gesamte Virusforsch. 1972;36(1):93–104. DOI: 10.1007/BF01250299

Delang L, Neyts J. Medical treatment options for COVID-19. Eur. Heart J. Acute Cardiovasc. Care; 2020, DOI: 10.1177/2048872620922790 DOI: 10.1016/j.ijantimicag.2020.105938

Martinez MA. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob. Agents Chemother. 2020;64:5. DOI: 10.1128/AAC.00399-20

Mulangu S et al. A randomized, controlled trial of ebola virus disease therapeutics. N. Engl. J. Med. 2019;381(24):2293–2303. DOI: 10.1056/NEJMoa1910993

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro | Cell Research. (accessed Sep. 22, 2020). Available:https://www.nature.com/articles/s41422-020-0282-0

Aremu SO et al. In-Vitro antimicrobial efficacy study of borreria verticillata stem bark extracts against some dermatophytes and drug resistant pathogens. Intl. J. Sci. Res Pub. ResearchGate. (accessed May 02, 2020). DOI: 10.29322/IJSRP.9.02.2019.p8668

Bamidele JO, Daniel OJ. Epidemiology of coronavirus disease (COVID-19) in Nigeria. Ann. Health Res. 2020;6(2):2. DOI: 10.30442/ahr.0602-01-74

Hens N, Vranck P, Molenberghs G. The COVID-19 epidemic, its mortality, and the role of non-pharmaceutical interventions. Eur. Heart J. Acute Cardiovasc. Care. 2020;9(3):204–208. DOI: 10.1177/2048872620924922

Oti VB, Ioannou M. Traveler’s infections: Understanding SARS-CoV-2 as a potential agent. Kesmas Natl. Public Health J. 2020; 15(2):2. DOI: 10.21109/kesmas.v15i2.3974

Gambardella C, Pagliuca R, Pomilla G, Gambardella A. ‘COVID-19 risk contagion: Organization and procedures in a South Italy geriatric oncology ward. J. Geriatr. Oncol. 2020;11(7):1187–1188. DOI: 10.1016/j.jgo.2020.05.008

Israel’s Sheba Hospital turns to telehealth to treat incoming coronavirus-exposed patients | MobiHealthNews. (accessed Sep. 22, 2020). Available:https://www.mobihealthnews.com/news/europe/israels-sheba-hospital-turns-telehealth-treat-incoming-coronavirus-exposed-patients

Chauhan V et al. Novel coronavirus (COVID-19): Leveraging telemedicine to optimize care while minimizing exposures and viral transmission. J. Emerg. Trauma Shock. 2020;13(1):20–24. DOI: 10.4103/JETS.JETS_32_20

Tolone S, Gambardella C, Brusciano L, del Genio G, Lucido FS, Docimo L. Telephonic triage before surgical ward admission and telemedicine during COVID-19 outbreak in Italy. Effective and easy procedures to reduce in-hospital positivity. Int. J. Surg. Lond. Engl. 2020;78:123–125. DOI: 10.1016/j.ijsu.2020.04.060

Reed HE, Mberu BU. Capitalizing on Nigeria’s demographic dividend: Reaping the benefits and diminishing the burdens. Etude Popul. Afr. Afr. Popul. Stud. 2014;27 (2):319–330. DOI: 10.11564/27-2-477

Ibekwe TS, Fasunla AJ. Telemedicine in otorhinolaryngological practice during COVID-19 pandemic. Niger. Med. J. 2020; 61(3)111. DOI: 10.4103/nmj.NMJ_201_20